MRI monitoring of Avastin™ antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer

Journal of Magnetic Resonance Imaging

Volumn 20, Issue 5, 2004, Pages 865-873

  Preda, Anda ^a,b   Novikov, Viktor ^a   Möglich, Martina ^a   Turetschek, Karl ^a   Shames, David M ^a   Brasch, Robert C ^a   Cavagna, Friedrich M ^c   Roberts, Timothy P L ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Bracco SpA   (Italy)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Contrast agent; Magnetic resonance imaging; Microvascular permeability; Therapy; Tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; B 22956 1; BEVACIZUMAB; CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOTERIDOL; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; COMPARTMENT MODEL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; MICROVASCULATURE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; RATS; RATS, NUDE;

EID: 7044253187     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.20184     Document Type: Article

References (47)

1. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994;4:207-218.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
3. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991;53:217-239.
4. Brown L, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91.
5. Warren RS, Yuan H, Matli MR, Gilett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
6. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-516.
7. Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993;91: 153-159.
8. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;60:203-212.
9. Kim JK, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-844.
10. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 1996;56:921-924.
11. Melnyk O, Zirnmerman M, Kim KJ, Shuman M. Neutralizing antivascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 1999;161:960-963.
12. Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59:5209-5218.
13. Okamoto K, Oshika Y, Fukushima Y, et al. Inhibition of liver metastasis of colon cancer by in vivo administration of anti-vascular endothelial growth factor antibody. Oncol Rep 1999;6:553-556.
14. Rowe DH, Huang J, Kayton ML, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms tumor. J Pediatr Surg 2000;35:30-32.
15. Huang J, Moore J, Soffer S, et al. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 2001;36:357-361.
16. Shaheen RM, Tseng WW, Vellagas R, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 2001;18:221-226.
17. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-589.
18. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998;171:941-949.
19. Schwickert HC, Stiskal M, Roberts TP, et al. Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. Radiology 1996;198:893-898.
20. Gossman A, Okuhata Y, Shames DM, et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media-preliminary experience. Radiology 1999;213:265-272.
21. Pham C, Roberts T, van Bruggen N, et al. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 1998;6:224-230.
22. Gossman A, Helbich TH, Mesiano S, et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol 2000;183: 956-963.
23. White D, Wang S-C, Aicher K, Dupon J, Engelstad B, Brasch R. Albumin-(Gd-DTPA) 15-20: whole body clearance, and organ distribution of gadolinium. In: Proceedings of the 8th Annual Meeting of SMRM. Amsterdam. The Netherlands. 1989. p 807.
24. Baxter AB, Melnikoff S, Stites DP, Brasch RC. Immunogenicity of gadolinium-based contrast agents for MRI. Invest Radiol 1991;26: 1035-1040.
25. Turetschek K, Huber S, Floyd E, et al. MR imaging characterization of microvessels in experimental breast tumors by using a paniculate contrast agent with histopathologic correlation. Radiology 2001;218:562-569.
26. Turetschek K, Roberts TPL, Floyd E, et al. Tumor microvascular characterization using ultrasmall superparamagnetic iron oxide particles (USPIO) in an experimental breast cancer model. J Magn Reson Imaging 2001;13:882-888.
27. Turetschek K, Floyd E, Helbich T, et al. MRI assessment of microvascular characteristics in experimental breast tumors using a new blood pool contrast agent (MS-325) with correlation to histopathology. J Magn Reson Imaging 2001;14:237-242.
28. Turetschek K, Floyd E, Shames DM, et al. Assessment of a rapid clearance blood pool MR contrast medium (P792) for assays of microvascular characteristics in experimental breast tumors with correlation to histopathology. Magn Reson Med 2001;45:880-886.
29. Sellappan S, Grijalva R, Zhoti X, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004;64:3479-3485.
30. Haase A. Snapshot FLASH MRI. Applications to T1, T2, and chemical shift imaging. Magn Reson Med 1990;13:77-89.
31. Schwickert HC, Roberts TP, Shames DM, et al. Quantification of liver blood volume: comparison of ultra short T1 inversion recovery echo planar imaging (ULSTIR-EP1), with dynamic 3D-gradient recalled echo imaging. Magn Reson Med 1995;34:845-852.
32. Cavagna FM, Zheng J, Lorusso V, Magionni F, Li D, Finn PJ. New protein binding Gd chelate with high vascular containment for MR coronary angiography. J Cardio Magn Reson 1999;1:387-388.
33. Zheng J, Carr J, Harris K, et al. Three-dimensional MR pulmonary perfusion imaging and angiography with an injection of a new blood pool contrast agent B-22956/1. J Magn Reson Imaging 2001;14: 425-432.
34. Schmiedl U, Ogan M, Moseley M, et al. Comparison of the contrast-enhancing properties of albumin-(Gd-DTPA) and Gd-DTPA at 2.0T: an experimental study in rats. AJR Am J Roentgenol 1986;147: 1263-1270.
35. Roberts TP. Physiologic measurements by contrast-enhanced MR imaging: expectations and limitations. J Magn Reson Imaging 1997;7:82-90.
36. Tofts PS, Kernmode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts. Magn Reson Med 1991;17:357-367.
37. Larsson HBW, Stubgaard M, Frederiksen JL, Jenssen M, Henriksen O, Paulson OB. Quantitation of blood-brain-barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumors. Magn Reson Med 1990; 16:117-131.
38. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991;15:621-628.
39. Shames D, Kuwatsuru R, Vexler V, Muhler A, Brasch RC. Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative non-invasive technique. Magn Reson Med 1993;29:616-622.
40. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-2935.
41. Van Dijke C, Brasch R, Roberts T, et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumor microvasculature and histologic capillary density. Radiology 1996;198:813-818.
42. Dvorak H, Nagy J, Dvorak J, Dvorak A. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133:95-109.
43. Prato F, Wisenberg G, Marshall T, Uksik P, Zabel P. Comparison of the biodistribution of gadolinium 153 DTPA and technetium-99m DTPA in rats. J Nucl Med 1988;29:1683-1687.
44. Tong C, Prato S, Wisenberg G, et al. Measurement of the extraction efficiency and distribution volume for Gd-DTPA in normal and diseased canine myocardium. Magn Reson Med 1993;30:337-346.
45. Turetschek K, Preda A, Floyd E, et al. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model. Eur J Nucl Med 2003;30:448-455.
46. Bremertch J, Roberts TPL, Wendland M, et al. Three-dimensional MR imaging of pulmonary vessels and parenchyma with NC100150 (Clariscan). J Magn Reson Imaging 2000;11:622-628.
47. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-14770.